Development of next generation vaccines based on nano particles

Purpose and goal:

The aim of the project was to submit a grant application for further development of new vaccines against diseases where the current alternatives are deficient. That goal is met.

We wanted to gather a consortium where expertise from different parts of the development phases work together, e.g. experts in specific pathogens, antigen research, heterologous and homologous membrane vesicle technology, GMP production, regulatory expertise and knowledge in pre-clinical and clinical development. Through various activities, we have managed to gather a unique and diversified group.

Expected results and effects:

The EU project will focus on the development of a platform based on membrane vesicles that create protection against respiratory diseases, control colonization and block transmission through intranasal vaccination.

New vaccines can be developed quickly by changing the antigen attached to the vesicles. Membrane vesicles have an intrinsic adjuvant activity.

As an example of the application of the technology, a universal vaccine against pneumococcus will be developed to the clinical phase and tested in a so-called Human Challenge model. Approach and implementation:

In WP1, we succeeded in creating a competitive and equal consortium with great knowledge and geographical diversification through some travels to build new contacts and through digital meetings with new and existing contacts. WP2 focused on evaluation of partners for the manufacturing of membrane vesicles and various methods, which took more time than planned but got good results and a competitive partner for the consortium.

In WP3 we carried out several studies and verification work on vaccines and manufacturing methods, which is the basis for the project plan in the application.